You are here

  • Home
  • Archive
  • Volume 82, Issue 2
  • Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Article info

Article menu
Download PDFPDF
Rheumatoid arthritis
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Authors

  • Lea Hoisnard Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, Île-de-France, France Centre d’Investigation Clinique 1430, INSERM, Créteil, Ile-de-France, France EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris ESt Créteil University UPEC, Créteil, France PubMed articlesGoogle scholar articles
  • Laura Pina Vegas Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, Île-de-France, France EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris ESt Créteil University UPEC, Créteil, France Department of Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France PubMed articlesGoogle scholar articles
  • Rosemay Dray-Spira EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France PubMed articlesGoogle scholar articles
  • Alain Weill EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France PubMed articlesGoogle scholar articles
  • Mahmoud Zureik EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France PubMed articlesGoogle scholar articles
  • Emilie Sbidian Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, Île-de-France, France Centre d’Investigation Clinique 1430, INSERM, Créteil, Ile-de-France, France EpiDermE Epidemiology in Dermatology and Evaluation of Therapeutics, EA7379, Paris ESt Créteil University UPEC, Créteil, France EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France Department of Dermatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Lea Hoisnard, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris, Paris, Île-de-France, France; lea.hoisnard{at}aphp.fr
View Full Text

Citation

Hoisnard L, Pina Vegas L, Dray-Spira R, et al
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Annals of the Rheumatic Diseases 2023;82:182-188.

Publication history

  • Received May 20, 2022
  • Accepted August 25, 2022
  • First published October 5, 2022.
Online issue publication 
January 23, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.